Table 3. Multivariate analysis of clinicopathologic factors for PFS.
| Factor | HR | 95% CI | P value |
|---|---|---|---|
| TTF-1 | |||
| Positive | Reference | ||
| Negative | 1.62 | 1.02–2.57 | 0.04 |
| Age | |||
| <75 years | Reference | ||
| ≥75 years | 1.89 | 0.90–3.96 | 0.09 |
| PD-L1 TPS | |||
| ≥50% | Reference | ||
| <50% | 1.38 | 0.82–2.32 | 0.22 |
| Smoking | |||
| Never-smoker | Reference | ||
| Smoker | 1.49 | 0.78–2.84 | 0.23 |
| Angiogenesis inhibitor added | |||
| Bevacizumab | Reference | ||
| None | 1.41 | 0.77–2.61 | 0.27 |
| Sex | |||
| Female | Reference | ||
| Male | 1.11 | 0.63–1.96 | 0.71 |
All P values were calculated with a proportional hazards regression model. PFS, progression-free survival; HR, hazard ration; CI, confidence interval; TTF-1, thyroid transcription factor 1; PD-L1, programmed cell death ligand 1; TPS, tumor proportion score.